PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor t...
Full description
Bibliographic Details
| Main Authors: |
Antoni Ribas,
Alain Algazi,
Paolo A. Ascierto,
Marcus O. Butler,
Sunandana Chandra,
Michael Gordon,
Leonel Hernandez-Aya,
Donald Lawrence,
Jose Lutzky,
Wilson H. Miller,
Katie M. Campbell,
Bruno Delafont,
Shannon Marshall,
Nancy Mueller,
Caroline Robert |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Publishing Group
2020-12-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-020-19810-w
|
|---|
